Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway

Journal of Biological Chemistry

Volumn 289, Issue 9, 2014, Pages 5654-5663

  Wang, Qiong ^a,b   Chen, Wenshu ^a   Bai, Lang ^a   Chen, Wenjie ^a   Padilla, Mabel T ^a   Lin, Amy S ^a   Shi, Shaoqing ^a,b   Wang, Xia ^b   Lin, Yong ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR REACTIVE OXYGEN SPECIES; CHEMO SENSITIZATIONS; CHEMOTHERAPY RESPONSE; INHIBITOR OF APOPTOSIS PROTEINS; PROTEASOMAL DEGRADATION; REACTIVE OXYGEN SPECIES; RECEPTOR-INTERACTING PROTEINS; X-LINKED INHIBITOR OF APOPTOSIS;

CELL DEATH; CHEMOTHERAPY; CYTOTOXICITY; PLATINUM COMPOUNDS; PROTEINS; RNA;

CELL SIGNALING;

CATALASE; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; MICRORNA 146A; REACTIVE OXYGEN METABOLITE; RECEPTOR INTERACTING PROTEIN 1; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CHEMOSENSITIZATION; CONTROLLED STUDY; ENZYME REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

APOPTOSIS; CHEMORESISTANCE; LUNG CANCER; REACTIVE OXYGEN SPECIES (ROS); RIP;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CATALASE; CELL LINE, TUMOR; CISPLATIN; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICRORNAS; NEOPLASMS; REACTIVE OXYGEN SPECIES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84896848468     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.526152     Document Type: Article

References (40)

1. Chang, A. (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71, 3-10
2. Maione, P., Rossi, A., Sacco, P. C., Bareschino, M. A., Schettino, C., and Gridelli, C. (2010) Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin. Pharmacother. 11, 2997-3007
3. Ulahannan, S. V., and Brahmer, J. R. (2011) Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest. 29, 325-337
4. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer. The next generation. Cell 144, 646-674
5. Lin, Y., Bai, L., Chen, W., and Xu, S. (2010) The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin. Ther. Targets 14, 45-55
6. Lin, Y., Choksi, S., Shen, H. M., Yang, Q. F., Hur, G. M., Kim, Y. S., Tran, J. H., Nedospasov, S. A., and Liu, Z. G. (2004) Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J. Biol. Chem. 279, 10822-10828 (Pubitemid 38372695)
7. Starkov, A. A. (2008) The role of mitochondria in reactive oxygen species metabolism and signaling. Ann. N.Y. Acad. Sci. 1147, 37-52
8. Trachootham, D., Alexandre, J., and Huang, P. (2009) Targeting cancer cells by ROS-mediated mechanisms. A radical therapeutic approach? Nat. Rev. Drug Discov. 8, 579-591
9. Bai, L., Xu, X., Wang, Q., Xu, S., Ju, W., Wang, X., Chen, W., He, W., Tang, H., and Lin, Y. (2012) A superoxide-mediated mitogen-activated protein kinase phosphatase-1 degradation and c-Jun NH(2)-terminal kinase activation pathway for luteolin-induced lung cancer cytotoxicity. Mol. Pharmacol. Drug Discov. 81, 549-555
10. Lin, Y., Shi, R., Wang, X., and Shen, H. M. (2008) Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr. Cancer Drug Targets 8, 634-646
11. Wang, J., and Yi, J. (2008) Cancer cell killing via ROS. To increase or decrease, that is the question. Cancer Biol. Ther. 7, 1875-1884
12. Festjens, N., Vanden Berghe, T., Cornelis, S., and Vandenabeele, P. (2007) RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 14, 400-410
13. Kelliher, M. A., Grimm, S., Ishida, Y., Kuo, F., Stanger, B. Z., and Leder, P. (1998) The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8, 297-303 (Pubitemid 28188890)
14. Ting, A. T., Pimentel-Muiños, F. X., and Seed, B. (1996) RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J. 15, 6189-6196 (Pubitemid 26397891)
15. Lin, Y., Devin, A., Cook, A., Keane, M. M., Kelliher, M., Lipkowitz, S., and Liu, Z. G. (2000) The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IκB kinase and c-Jun N-terminal kinase. Mol. Cell. Biol. 20, 6638-6645
16. Meylan, E., and Tschopp, J. (2005) The RIP kinases. Crucial integrators of cellular stress. Trends Biochem. Sci. 30, 151-159 (Pubitemid 40332531)
17. Kaiser, W. J., and Offermann, M. K. (2005) Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J. Immunol. 174, 4942-4952 (Pubitemid 40514460)
18. Hur, G. M., Lewis, J., Yang, Q., Lin, Y., Nakano, H., Nedospasov, S., and Liu, Z. G. (2003) The death domain kinase RIP has an essential role in DNA damage-induced NF-κB activation. Genes Dev. 17, 873-882 (Pubitemid 36397375)
19. Park, J., Kanayama, A., Yamamoto, K., and Miyamoto, Y. (2012) ARD1 binding to RIP1 mediates doxorubicin-induced NF-κB activation. Biochem. Biophys. Res. Commun. 422, 291-297
20. Wang, L., Du, F., and Wang, X. (2008) TNF-α induces two distinct caspase-8 activation pathways. Cell 133, 693-703 (Pubitemid 351636305)
21. Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J. L., Schneider, P., Seed, B., and Tschopp, J. (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1, 489-495
22. Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg, F., Zachariou, A., Lopez, J., MacFarlane, M., Cain, K., and Meier, P. (2011) The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 43, 432-448
23. Bai, L., Chen, W., Chen, W., Wang, X., Tang, H., and Lin, Y. (2009) IKKβ-mediated nuclear factor-κB activation attenuates Smac mimetic-induced apoptosis in cancer cells. Mol. Cancer Ther. 8, 1636-1645
24. Wang, X., Chen, W., and Lin, Y. (2007) Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-κB and Akt pathways. Biochem. Biophys. Res. Commun. 355, 807-812 (Pubitemid 46330225)
25. Ju, W., Wang, X., Shi, H., Chen, W., Belinsky, S. A., and Lin, Y. (2007) A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-κB pathway and sensitization of apoptosis in lung cancer cells. Mol. Pharmacol. 71, 1381-1388 (Pubitemid 46658691)
26. Sakon, S., Xue, X., Takekawa, M., Sasazuki, T., Okazaki, T., Kojima, Y., Piao, J. H., Yagita, H., Okumura, K., Doi, T., and Nakano, H. (2003) NF-κB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J. 22, 3898-3909 (Pubitemid 36975716)
27. Yang, L., Wang, Q., Li, D., Zhou, Y., Zheng, X., Sun, H., Yan, J., Zhang, L., Lin, Y., and Wang, X. (2013) Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins. Apoptosis 18, 618-626
28. He, W., Wang, Q., Xu, J., Xu, X., Padilla, M. T., Ren, G., Gou, X., and Lin, Y. (2012) Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy 8, 1811-1821
29. Yang, Y., Xia, F., Hermance, N., Mabb, A., Simonson, S., Morrissey, S., Gandhi, P., Munson, M., Miyamoto, S., and Kelliher, M. A. (2011) A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-κB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol. Cell. Biol. 31, 2774-2786
30. Löder, S., Fakler, M., Schoeneberger, H., Cristofanon, S., Leibacher, J., Vanlangenakker, N., Bertrand, M. J., Vandenabeele, P., Jeremias, I., Debatin, K. M., and Fulda, S. (2012) RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 26, 1020-1029
31. Basit, F., Humphreys, R., and Fulda, S. (2012) RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis. J. Biol. Chem. 287, 38767-38777
32. Caputo, F., Vegliante, R., and Ghibelli, L. (2012) Redox modulation of the DNA damage response. Biochem. Pharmacol. 84, 1292-1306
33. Wang, Q., Chen, W., Xu, X., Li, B., He, W., Padilla, M. T., Jang, J. H., Nyunoya, T., Amin, S., Wang, X., and Lin, Y. (2013) RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. Carcinogenesis 34, 2119-2128
34. Epperly, M. W., Melendez, J. A., Zhang, X., Nie, S., Pearce, L., Peterson, J., Franicola, D., Dixon, T., Greenberger, B. A., Komanduri, P., Wang, H., and Greenberger, J. S. (2009) Mitochondrial targeting of a catalase transgene product by plasmid liposomes increases radioresistance in vitro and in vivo. Radiat. Res. 171, 588-595
35. Bauer, G. (2012) Tumor cell-protective catalase as a novel target for rational therapeutic approaches based on specific intercellular ROS signaling. Anticancer Res. 32, 2599-2624
36. LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., and Korneluk, R. G. (2008) IAP-targeted therapies for cancer. Oncogene 27, 6252-6275
37. Krepler, C., Chunduru, S. K., Halloran, M. B., He, X., Xiao, M., Vultur, A., Villanueva, J., Mitsuuchi, Y., Neiman, E. M., Benetatos, C., Nathanson, K. L., Amaravadi, R. K., Pehamberger, H., McKinlay, M., and Herlyn, M. (2013) The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin. Cancer Res. 19, 1784-1794
38. Dynek, J. N., Goncharov, T., Dueber, E. C., Fedorova, A. V., Izrael-Tomasevic, A., Phu, L., Helgason, E., Fairbrother, W. J., Deshayes, K., Kirkpatrick, D. S., and Vucic, D. (2010) c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 29, 4198-4209
39. Varfolomeev, E., Goncharov, T., Fedorova, A. V., Dynek, J. N., Zobel, K., Deshayes, K., Fairbrother, W. J., and Vucic, D. (2008) c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor α (TNFα)-induced NF-κB activation. J. Biol. Chem. 283, 24295-24299
40. Vanlangenakker, N., Vanden Berghe, T., and Vandenabeele, P. (2012) Many stimuli pull the necrotic trigger. An overview. Cell Death Differ. 19, 75-86